Document is current
Any future updates will be listed below
-
Authors
Duran, Imanol https://orcid.org/0000-0001-6615-3788
Pombo, Joaquim
Sun, Bin https://orcid.org/0000-0002-8963-4100
Gallage, Suchira https://orcid.org/0000-0002-1956-3597
Kudo, Hiromi
McHugh, Domhnall
Bousset, Laura https://orcid.org/0000-0002-5339-3173
Barragan Avila, Jose Efren https://orcid.org/0000-0002-9348-909X
Forlano, Roberta https://orcid.org/0000-0003-4746-7065
Manousou, Pinelopi
Heikenwalder, Mathias
Withers, Dominic J. https://orcid.org/0000-0002-8009-7521
Vernia, Santiago https://orcid.org/0000-0001-6728-5555
Goldin, Robert D. https://orcid.org/0000-0001-5184-4519
Gil, Jesús https://orcid.org/0000-0002-4303-6260
- License Information
-
More Information
Article History
Received: 29 June 2023
Accepted: 22 January 2024
First Online: 3 February 2024
Competing interests
: J.G. has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma, and Merck KGaA. Pfizer and Unity Biotechnology have funded research in J.G.’s lab (unrelated to the work presented here). J.G. owns equity in Geras Bio. J.G. is a named inventor in MRC and Imperial College patents, both related to senolytic therapies (the patents are not related to the work presented here). The remaining authors declare no competing interests.
